For more than 30 years, the 340B Drug Pricing Program has provided financial help to hospitals serving vulnerable communities to manage rising prescription drug costs.

What is the 340B Program? This program, administered by the Health Resources and Services Administration (HRSA), allows 340B hospitals to stretch limited federal resources to reduce the price of outpatient pharmaceuticals for patients and expand health services to the patients and communities they serve. Hospitals use 340B savings to provide, for example, free care for uninsured patients, offer free vaccines, provide services in mental health clinics, and implement medication management and community health programs. According to HRSA, enrolled hospitals and other covered entities can achieve average savings of 25% to 50% in pharmaceutical purchases.

Which organizations are eligible? Several types of hospitals are eligible to participate in the 340B program including critical access hospitals (CAHs), sole community hospitals (SCHs), rural referral centers (RRCs), public and private nonprofit disproportionate share hospitals (DSHs) that serve high numbers of low-income and indigent populations, and free-standing cancer and children’s hospitals. Several types of federal grantee organizations such as community health centers also are eligible to participate in the program.

What are some challenges to the program? Despite rigorous oversight from HRSA and the program’s proven record of expanding access to care for Americans nationwide, critics continue to push to diminish the scope of the program and the benefits it affords eligible providers and their patients.
 

340B Resources

 

Member Resources


 

Join the 340B Alliance Banner

The AHA Advocacy Alliance for the 340B program focuses on promoting the value that the 340B program provides to hospitals, patients and communities, as well as preventing attempts to scale back this program. Join the alliance for access to email communications, conference calls and special briefings. Join the Alliance.


Through email communications like alliance emails, action alerts and special messages, the 340B Alliance keeps hospitals informed of the latest news and developments on the program, as well as actions hospital leaders can take to support the program. Learn More

 

Image of medicine in pharmacy

 

Latest 340B Content

Headline
The AHA Jan. 26 urged the Health Resources and Services Administration to take immediate action to stop a new Eli Lilly and Company policy from taking effect on Feb. 1, including by “assessing civil monetary penalties for intentionally overcharging 340B hospitals.”
Advisory
The House of Representatives Jan. 22 voted 341-88 to pass the Consolidated Appropriations Act of 2026 (H.R.7148), which contains conferenced legislation for the Departments of Defense, Homeland Security, Labor, Health and Human Services, Education, Transportation, and Housing and Urban Development.
340B Advocacy Alliance Bulletin
AHA urges HRSA to stop Eli Lilly’s new claims-data submission policy on 340B hospitals from going into effect; hospitals urged to submit their own letters to HRSA and use AHA letter as a guide.
Letter/Comment
The American Hospital Association (AHA) expresses serious concerns with the recent announcement by Eli Lilly and Company (Lilly) to require 340B covered entities to submit claims data for all dispensations of all Lilly drugs, regardless of setting.
Headline
The federal government has dropped its appeal of a preliminary injunction blocking implementation of the Department of Health and Human Services’ 340B Rebate Model Pilot Program.
340B Advocacy Alliance Bulletin
Several health care groups, including the AHA, today told the Centers for Medicare & Medicaid Services it is wrong to tell hospitals and health systems they “are to” complete the agency’s Outpatient Prospective Payment System Drug Acquisition Cost Survey and urged CMS to correct an FAQ issued on the issue.
Press Releases
The First Circuit recognized that the district court’s decision halting the 340B Rebate Program was “careful and thorough”— and correct. The AHA remains pleased that these courts have put on hold this harmful program that would have a devastating effect on America’s most vulnerable patients and communities, and the hospitals that serve them.
Headline
The 1st U.S. Circuit Court of Appeals Jan. 7 denied the government’s motion for a stay in a lawsuit filed by the AHA, the Maine Hospital Association and four safety-net health systems challenging the Department of Health and Human Services’ 340B Rebate Model Pilot Program. This means that the program remains on hold.
340B Advocacy Alliance Bulletin
The United States Court of Appeals for the First Circuit today denied the government’s motion for a stay in a lawsuit filed by the AHA, the Maine Hospital Association, and four safety-net health systems challenging the 340B Rebate Model Pilot Program.
Case Studies
Door County Medical Center (DCMC) has been serving the people of Door and Kewaunee counties in Wisconsin for more than 80 years.